Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
